Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
PODCAST | Product Development

CRISPR lessons; plus AbbVie enters obesity — a BioCentury podcast

BioCentury’s editors also discuss recommendations for early stage rare disease drug development

March 4, 2025 12:45 AM UTC

The track record of biotechs launched to create curative therapies using CRISPR-Cas9 provides new insights into the old debate over whether platform companies should validate their technology on established targets or pursue new ones. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the lessons learned by this small group of companies since their launch a decade ago.

They also discuss the entrance of AbbVie Inc. (NYSE:ABBV) into the obesity race via a $350 million deal with Gubra A/S (CSE:GUBRA) for a clinical stage amylin agonist — does it signal AbbVie’s belief in amylin monotherapy, or will the company be hunting for more obesity assets? The editors also talk about recommendations to streamline the early-stage development of rare disease therapies in the U.S.

Purchase Reprint/Distribution Rights
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Abbvie Inc.

Gubra A/S

BCIQ Target Profiles

Amylin receptor